Literature DB >> 23601576

Usefulness of monocyte chemoattractant protein-1 to predict no-reflow and three-year mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Eyup Buyukkaya1, Fatih Poyraz, Mehmet F Karakas, Mustafa Kurt, Adnan B Akcay, Ibrahim Akpinar, Sedat Motor, Osman Turak, Oktay H Ozturk, Nihat Sen, Mahmut Akpek, Mehmet G Kaya, C Michael Gibson.   

Abstract

Although monocyte chemoattractant protein-1 (MCP-1) levels are increased in patients with ST-segment elevation myocardial infarction, the prognostic value of MCP-1 in primary percutaneous coronary intervention (pPCI) is not clear. The goal of the present study was to investigate the association of MCP-1 levels with myocardial perfusion and prognosis in patients with ST-segment elevation myocardial infarction undergoing pPCI. Consecutive pPCI patients (n = 192) were assigned to tertiles according to their admission serum MCP-1 levels. Angiographic no-reflow, Thrombolysis In Myocardial Infarction flow grade, myocardial blush grade, and ST-segment resolution were assessed. Mortality and major adverse cardiac events were evaluated during hospitalization and at the 3-year clinical follow-up visit. Failure of ST resolution was associated with greater admission MCP-1 levels. The risk of no-reflow (Thrombolysis In Myocardial Infarction flow ≤2 or Thrombolysis In Myocardial Infarction flow 3 with final myocardial blush grade ≤2 after pPCI and ST resolution <30%) increased as the admission MCP-1 increased. The 3-year mortality increased as the MCP-1 level increased (8% vs 22% vs 28% for the 3 tertiles, p <0.01). Multivariate logistic regression analysis demonstrated that MCP-1 levels at admission are a significant independent correlate of 3-year mortality in patients with no-reflow as detected by myocardial blush grade. A receiver operating characteristics analysis identified an optimum cut point of ≥254 pg/ml, which was associated with a negative predictive value of 95% in association with 1-year mortality. In conclusion, the plasma MCP-1 levels at admission are independently associated with the development of no-reflow and 3-year mortality in patients with ST-segment elevation myocardial infarction undergoing pPCI. Crown
Copyright © 2013. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23601576     DOI: 10.1016/j.amjcard.2013.03.011

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Impact of D-dimer level on postinterventional coronary flow and in-hospital MACE in ST-segment elevation myocardial infarction.

Authors:  B Sarli; M Akpek; A O Baktir; O Sahin; H Saglam; H Arinc; H Odabasi; S Dogan; S Kurtul; Y Dogan; M G Kaya
Journal:  Herz       Date:  2014-01-19       Impact factor: 1.443

2.  Characterization of the yeast tricalbins: membrane-bound multi-C2-domain proteins that form complexes involved in membrane trafficking.

Authors:  C E Creutz; S L Snyder; T A Schulz
Journal:  Cell Mol Life Sci       Date:  2004-05       Impact factor: 9.261

3.  Percutaneous Transluminal Angioplasty in Patients with Peripheral Arterial Disease Does Not Affect Circulating Monocyte Subpopulations.

Authors:  Pawel Maga; Tomasz P Mikolajczyk; Lukasz Partyka; Marek Krzanowski; Krzysztof P Malinowski; Rafal Nizankowski
Journal:  Biomed Res Int       Date:  2016-10-13       Impact factor: 3.411

4.  Effect of Chinese national holidays and weekends versus weekday admission on clinical outcomes in patients with STEMI undergoing primary PCI.

Authors:  Liang Tang; Peng-Fei Chen; Xin-Qun Hu; Xiang-Qian Shen; Yan-Shu Zhao; Zhen-Fei Fang; Sheng-Hua Zhou
Journal:  J Geriatr Cardiol       Date:  2017-10       Impact factor: 3.327

5.  Predicting coronary no-reflow in patients with acute ST-segment elevation myocardial infarction using Bayesian approaches.

Authors:  Dongfeng Zhang; Xiantao Song; Shuzheng Lv; Dong Li; Shuai Yan; Min Zhang
Journal:  Coron Artery Dis       Date:  2014-11       Impact factor: 1.439

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.